A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growth

Cancer Gene Therapy

Volumn 5, Issue 4, 1998, Pages 207-214

  Demers, G William ^a   Harris, Matthew P ^a   Wen, Shu Fen ^a   Engler, Heidrun ^a   Nielsen, Loretta L ^a   Maneval, Daniel C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Gene therapy; Gene transfer; Retinoblastoma genes; Tumor suppressor genes

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE; RECOMBINANT PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; CELL CULTURE; CELL CYCLE G1 PHASE; CELL DIVISION; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; RETINOBLASTOMA;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; GENE THERAPY; GENETIC VECTORS; HUMANS; L-LACTATE DEHYDROGENASE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS; RETINOBLASTOMA; TUMOR CELLS, CULTURED;

EID: 0032113877     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
2. 1 phase of the cell cycle. Cell. 1991;67:293-302.
3. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature. 1992;358:259-261.
4. Wiman KG. The retinoblastoma gene: role in cell cycle control and cell differentiation. FASEB J. 1993;7:841-845.
5. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Alberts DM, Dryja TP. A human DNA segment with the properties of the gene that predisposes to retinoblastoma and osteosarcoma. Proc Natl Acad Sci USA. 1986;83: 7391-7394.
6. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EYHP. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science. 1987;235:1394-1399.
7. Yokota J, Akiyama T, Fung YKT, Benedict WF, Namba Y, Hanaoka M, Wada M, Terasaki T, Shimosato Y, Sugimura T, Terada M. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene. 1988;3:471-475.
8. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988; 241:353-356.
9. Horowitz JM, Yandell DW, Park SH, Canning S, Whyte P, Buchkovich K, Harlow E, Weinberg RA, Dryja TP. Point mutational inactivation of the retinoblastoma antioncogene. Science. 1989;243:937-940.
10. Horowitz JM, Park SH, Bogenmann E, Chang JC, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA. 1990;87:2775-2779.
11. Lee EYHP, To H, Shew JY, Bookstein R, Scully P, Lee WH. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science. 1988;241:218-221.
12. T'Ang A, Varley JM, Chakraborty S, Murphree AL, Fung YKT. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science. 1988;242:263-266.
13. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 1997;57: 1217-1221.
14. Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer. 1993;53:781-784.
15. Wang NP, To H, Lee WH, Lee EYHP. Tumor suppressor activity of Rb and p53 genes in human breast carcinoma cells. Oncogene. 1993;8:279-288.
16. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science. 1990;247:712-715.
17. Huang HJS, Yee JK, Shew JY, Chen PL, Bookstein R, Friedmann T, Lee EYHP, Lee WH. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science. 1988;242:1563-1566.
18. Madreperla SA, Whittum-Hudson JA, Prendergast RA, Chen PL, Lee WH. Intraocular tumor suppression of retinoblastoma gene-reconstituted retinoblastoma cells. Cancer Res. 1991;51:6381-6384.
19. Takahashi R, Hashimoto T, Xu HJ, Hu SX, Matsui T, Miki T, Bigo-Marshall H, Aaronson SA, Benedict WF. The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci USA. 1991;88:5227-5261.
20. Rich DP, Couture LA, Cardoza LM, Guiggio VM, Armentano D, Espino PC, Hehir K, Welsh MJ, Smith AE, Gregory RJ. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum Gene Ther. 1993;4:461-476.
21. Bookstein R, Demers W, Gregory R, Maneval D, Park J, Wills K. p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol. 1996;23: 66-77.
22. Bass C, Cabrera G, Elgavish A, Robert B, Siegal GP, Anderson SC, Maneval DC, Curiel DT. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther. 1995;2:97-104.
23. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, Shaked A. Adenoviral p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol. 1996;155:753-756.
24. Huang S, Lee WH, Lee EYHP. A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product. Nature. 1991;350:160-162.
25. Wills KN, Huang WM, Harris MP, Machemer T, Maneval DC, Gregory RJ. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 1995;2:191-197.
26. Smith RC, Wills KN, Antelman D, Perlman H, Truong LN, Krasinski K, Walsh K. Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation. 1997;96:1899-1905.
27. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, Huang WM, Johnson DE, Anderson SC, Wen SF, Bookstein R, Shepard HM, Gregory RJ. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther. 1994;5:1079-1088.
28. Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard HM, Scandella CJ, Shabram P. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther. 1995;6:1403-1416.
29. Maizel J, White D, Scharff M. The polypeptides of adenovirus 1: evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology. 1968;36:115-125.
30. March KL, Madison JE, Trapnell BC. Pharmokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implications for cardiovascular gene therapy. Hum Gene Ther. 1995:6:41-53.
31. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA. 1991;88: 4626-4630.
32. Wen SF, Nodelman M, Nared-Hood K, Duncan J, Geradts J, Shepard HM. Retinoblastoma protein monoclonal antibodies with novel characteristics. J Immunol Methods. 1994;169:231-240.
33. Kock H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, Wills KN, Gregory RJ, Shepard HM, Westphal M, Maneval DC. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer. 1996;67:808-815.
34. Williamson MP, Elder PA, Knowles MA. The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer. 1994;9:108-118.
35. Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes and Development. 1992;6:177-185.
36. Xu HJ, Zhou Y, Seigne J, Perng GS, Mixon M, Zhang C, Li J, Benedict WF, Hu SX. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res. 1996;56:2245-2249.
37. DeCaprio JA, Furukawa Y, Ajchenbaum F, Griffen J, Livingston DM. The retinoblastoma susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci USA. 1992;89:1795-1798.
38. Teramoto S, Johnson LG, Huang W, Leigh MW, Boucher RC. Effect of adenoviral vector infection on cell proliferation in cultured primary human airway epithelial cells. Hum Gene Ther. 1995;6:1045-1053.
39. Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, Kao C, Chung LW. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther. 1996;7:1683-1691.
40. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA. 1994;91:6196-6200.
41. Wang Q, Jia XC, Finer MH. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. 1995;2:775-783.
42. Bignon YJ, Chen Y, Chang CY, Riley DJ, Windle JJ, Mellon PL, Lee WH. Expression of a retinoblastoma transgene results in dwarf mice. Genes Dev. 1993;7:1654-1662.
43. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995; 267:518-522.
44. Banerjee A, Xu HJ, Hu SX, Araujo D, Takahashi R, Stanbridge EJ, Benedict WF. Changes in growth and tumorigenicity following reconstitution of retinoblastoma gene function in various human cancer cell types by microcell transfer of chromosome 13. Cancer Res. 1992;52: 6297-6304.
45. Antelman D, Machemer T, Huyghe BG, Shepard HM, Maneval D, Johnson DE. Inhibition of tumor cell proliferation in vitro and in vivo by exogenous p110RB, the retinoblastoma tumor suppressor protein. Oncogene. 1995; 10:697-704.
46. +/- mice. Nat Med. 1996; 2:1316-1321.